Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody
Marstacimab
Brand names: Hympavzi
Adult dose
Dose: Loading 300mg SC; then 150mg SC weekly
Route: SC
Frequency: weekly
Clinical pearls
- Routine prophylaxis for haemophilia A or B without inhibitors; specialist haematology
Contraindications
- Hypersensitivity
Side effects
- Injection site reactions
- Headache
- Pruritus
- Thrombosis (theoretical)
Interactions
- Other anticoagulants/haemostatics — caution
Monitoring
- Bleeding/thrombosis surveillance
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/marstacimab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Insulin Correction Factor (ICF/ISF) · Insulin Management
- R Factor for Drug-Induced Liver Injury (DILI) · Liver Disease
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO